Retatrutide vs Tirzepatide 2026: Triple Agonist vs Mounjaro Compared for Vietnam Buyers

You have been on tirzepatide for eight months in HCMC. The first 15kg came off fast. The last 3kg have taken twice as long. You have hit the plateau everyone warned you about, and now a friend in the expat health group keeps mentioning retatrutide. He lost 6kg in the first 10 weeks after switching. You want to know if it is worth the upgrade, or if you should just push through on tirzepatide.

This is the actual question people are asking. Not the clinical-journal version. The practical, I-live-in-Vietnam, I-source-both-compounds version. This guide answers that.

Both drugs work. Both are used by thousands of people in Vietnam right now, split between pharmacy pens and research-grade vials. The real question is which one fits your situation, and where the tradeoffs actually matter. Let's get into it.

Quick Comparison

The Short Answer for Vietnam Buyers

How They Work

Tirzepatide and retatrutide belong to the same broad class (incretin mimetics) but activate a different number of receptors. Tirzepatide hits two. Retatrutide hits three. That one extra receptor changes the whole metabolic profile of the drug.

GLP-1 and GIP (the two receptors tirzepatide targets) primarily work on appetite and insulin response. They signal satiety to the brain, slow gastric emptying so you feel full longer, and improve glucose disposal. The weight loss is driven almost entirely by eating less. Tirzepatide does not directly change how much energy your body burns at rest.

Retatrutide adds the glucagon receptor. Glucagon in this context is not the blood sugar rescue hormone most people know. When pulsed chronically through a peptide drug, glucagon activates hepatic (liver) fat oxidation, increases basal metabolic rate, and shifts the body toward burning stored fat as fuel even at rest. That is the mechanism responsible for the extra 2 to 5 percentage points of weight loss retatrutide shows over tirzepatide at equivalent time points.

Sources: Jastreboff et al., NEJM 2023 (retatrutide Phase 2), SURMOUNT-1 NEJM 2022, TRIUMPH-1 trial registration.

Weight Loss Results Compared

Tirzepatide results come from Phase 3 data, the SURMOUNT trial program, which is the gold standard for obesity drug evidence. Retatrutide results are Phase 2 data (Jastreboff et al., NEJM 2023), with Phase 3 (TRIUMPH) still in progress through 2026. That is why the 72-week retatrutide row below says "pending." TRIUMPH-1 primary outcomes are expected to read out in late 2026 or early 2027.

The gap widens over time. Retatrutide's glucagon activation creates additional fat burning that compounds alongside the appetite effect shared with tirzepatide. In practical terms, retatrutide users tend to continue losing weight at weeks 30 to 48 when tirzepatide users often start to plateau.

Individual variation is large on both drugs. About 10 to 15 percent of users on either compound are low responders and will stall at 8 to 10 percent total body weight loss. Another 10 to 15 percent are super-responders who exceed the averages by several points. The numbers in the table are means, not guarantees.

Community reports from Vietnam expats track the Phase 2 data closely. People switching from tirzepatide to retatrutide after a plateau typically see another 3 to 5kg drop in the first 8 to 12 weeks on retatrutide. People starting fresh on retatrutide often see 10kg+ in the first 12 weeks. These are anecdotal but consistent.

Side Effects: Real-World Comparison

Side effects are the number one reason people quit GLP-1 drugs, not efficacy. Tirzepatide and retatrutide share most side effects but differ in intensity and timing. Here is the honest breakdown.

GI effects (nausea, diarrhea, constipation). In the SURMOUNT-1 trial, nausea occurred in about 28 percent of tirzepatide users and diarrhea in 23 percent. Retatrutide Phase 2 data showed nausea in 36 percent and diarrhea in 29 percent at the 12mg dose. Both are manageable with slow titration. The first 2 weeks after each dose increase are the worst window.

Injection site reactions. Minor redness or itching at the injection site occurs in about 5 to 8 percent of users on either compound. Rotate sites (abdomen, thigh, upper arm) and let the solution reach room temperature before injecting. Reactions almost always resolve within 24 hours.

Heart rate. Retatrutide showed small mean heart rate increases (roughly 4 to 7 bpm) at higher doses in trial data. Tirzepatide does not show this effect. If you have an underlying heart condition or are monitoring variability via wearable, this is worth knowing. It is not dangerous for otherwise healthy users but it is a real physiological difference.

Gallbladder risk. Both drugs carry an elevated gallstone risk that scales with total weight loss. Users losing over 20 percent of body weight have measurably higher gallstone incidence regardless of compound. If you have a history of gallbladder issues, discuss with a physician before starting either.

Muscle loss.Any rapid weight loss drug carries a muscle loss concern. Retatrutide's more aggressive fat oxidation profile amplifies this if protein intake and resistance training are neglected. Aim for 1.6 to 2.2g protein per kg of goal body weight and train 2 to 3 times per week to preserve lean mass on either compound.

Micronutrient monitoring. Both drugs reduce food intake significantly, which can lead to B12, iron, and vitamin D deficiencies over months of use. Get bloodwork every 3 to 4 months, especially on retatrutide where caloric intake drops harder in the first phase.

For a full protocol on minimizing GI side effects during dose escalation on either drug, see the GLP-1 side effects management guide.

Which Should You Choose?

Dosing Comparison

Titration philosophy matters more than peak dose. Both drugs use a slow 4-week step-up to let your GI system adapt to the GLP-1 signal. Skipping titration will produce severe nausea, vomiting, and in some cases dehydration requiring medical attention. Do not start at a high dose because you read someone online did. Your gut will not forgive you.

Retatrutide dosing is still being refined since the drug is in Phase 3. The Phase 2 data used 1mg to 12mg weekly, with 8mg and 12mg producing the best weight loss outcomes. Current research consensus points to 8 to 12mg as the therapeutic sweet spot for most users. Some protocols go higher, but side effects climb sharply above 12mg without proportional efficacy gain.

If you plateau on either drug, the fix is rarely to jump the dose. Plateaus at mid-protocol usually reflect adaptive metabolic slowdown, not insufficient drug. Hold the current dose for an additional 4 weeks, tighten protein intake, and add resistance training before escalating. Dose escalation works best as the last lever, not the first.

Vietnam-Specific Considerations

This section is why this guide exists. Most comparison articles online are written for US or UK readers. Here is what actually matters if you are buying either drug in Vietnam.

Access. Mounjaro (tirzepatide) is pharmacy-available in Vietnam with a prescription from any international hospital (FV, Vinmec, Family Medical Practice). Stock is intermittent but reliable enough to plan around. Retatrutide is research-grade only. No pharmacy in Vietnam stocks retatrutide, and none will for at least 2 to 3 more years until FDA approval and DAV registration clear.

Pricing breakdown in VND. Pharmacy tirzepatide (branded Mounjaro or Zepbound) runs 4 to 6 million VND per pen at FV or Vinmec, with a pen lasting 4 weeks at starting doses or 2 weeks at higher doses. Research-grade tirzepatide runs 2 to 3 million VND per 10mg vial from verified domestic suppliers, which lasts 4 weeks at the 2.5mg starting dose. Research-grade retatrutide runs 4 to 6 million VND per 20mg vial. At standard protocol, the monthly cost comparison is roughly: research tirzepatide at 2.5 to 3.5 million VND, research retatrutide at around 5 million VND, pharmacy tirzepatide at 5 to 6 million VND.

Cold chain considerations. HCMC and Hanoi summer temperatures regularly hit 35 to 40 Celsius. Both compounds require refrigeration between 2 and 8 Celsius. Shipping with gel packs in insulated packaging is non-negotiable. Unreconstituted retatrutide is slightly more heat-stable in lyophilized form than reconstituted tirzepatide in solution, but neither will survive a day in a hot car or a non-refrigerated hotel mini-fridge. Always request express shipping during Vietnamese summer.

Customs considerations. Research-grade compounds shipped from international suppliers (China, EU, US) face customs inspection at entry. Vietnam customs do not actively target personal quantities, but seizures happen on oversized orders or unclear labeling. Domestic Vietnamese suppliers do not hit customs, which is why most expats switch to local after their first international attempt. Full legal context is in the peptide legality guide.

Physician oversight. If you are going the pharmacy route for tirzepatide, you will need lab work and a prescription. FV Hospital and Vinmec in both cities have endocrinologists who understand GLP-1s. If you are going research-grade on either compound, you still want baseline labs. The HCMC peptide guide and Hanoi peptide guide cover physician options in each city.

How people actually stack them.The most common pattern in the Vietnam expat community is to start on tirzepatide for 3 to 4 months to confirm GI tolerance and establish baseline response, then switch to retatrutide once stable. This order matters. Tirzepatide has the milder GI profile, so starting there catches anyone who is a non-responder or can't tolerate GLP-1s before committing to the more expensive retatrutide supply chain. If tirzepatide works well and results are sufficient, people stay there. If weight loss plateaus, the switch pays off.

The Verdict

Both are excellent options. The best choice depends on your risk tolerance, your weight loss target, and how you want to access the drug.

What Vietnam Users Report

The following patterns come from community reports in Vietnam expat health groups through 2025 and 2026. These are anecdotal, not clinical claims.

The most consistent pattern reported is the tirzepatide-to-retatrutide switch curve. Users who plateau on tirzepatide at 15 to 18 percent total body weight loss, hold for 6 to 8 weeks, then switch to retatrutide typically see another 3 to 5kg drop in the first 8 weeks on retatrutide. This matches the Phase 2 data closely.

The second pattern is GI tolerability at titration. Most first-time retatrutide users report more intense nausea and appetite loss in the first 2 weeks after each dose step compared to their tirzepatide experience. The intensity drops sharply by week 4 to 6. Users who switched from tirzepatide often describe retatrutide as "more noticeable" rather than "worse," which tracks with the slightly higher GI incidence in trial data.

The third pattern is cost-per-kg-lost. Retatrutide costs more per milligram and per month, but because users lose weight faster and reach their target sooner, total cost of the weight loss journey often comes out favorable compared to a longer tirzepatide run. A typical 20kg target reached in 8 months on retatrutide can cost roughly the same as reaching it in 12 months on tirzepatide, depending on dose requirements.

Availability in Vietnam

Frequently Asked Questions